Skip to content
Descubridor Institucional UMAR
Inicio
Búsqueda avanzada
Explorar
Inicio
Búsqueda avanzada
Explorar
Login
Language
English
Deutsch
Español
Français
Italiano
All Fields
Title
Author
Subject
Call Number
ISBN/ISSN
Tag
Find
Advanced
Low‐Dose Golidocitinib for Triple‐Mutant (JAK1/STAT3/TET2) ITLPD‐GI After DLBCL Remission
Low‐Dose Golidocitinib for Triple‐Mutant (JAK1/STAT3/TET2) ITLPD‐GI After DLBCL Remission
Fuente:
Wiley Open Access
Saved in:
Bibliographic Details
Main Authors:
Wenwen Wang
,
Zhengying Ruan
,
Jianlin Chen
Format:
Artículo Open Access
Published:
Wiley
2026
Subjects:
Hematological Oncology
Online Access:
Acceder al recurso
Tags:
Add Tag
No Tags, Be the first to tag this record!
Cite this
Text this
Email this
Print
Export Record
Export to RefWorks
Export to EndNoteWeb
Export to EndNote
Save to List
Permanent link
Holdings
Description
Comments
Similar Items
Staff View
Description
DOI:
10.1002/hon.70204
Similar Items
169 | PHOSPHO‐STAT3 EXPRESSION AND JAK/STAT PATHWAY ACTIVATION ACROSS GENETIC SUBTYPES OF DIFFUSE LARGE B‐CELL LYMPHOMA
by: A. A. Pomares, et al.
Published: (2025)
479 | DLBCL‐ASSOCIATED PIM1 MUTATION DRIVES ANXA2 RELOCATION ON THE MEMBRANE AND PROMOTES LYMPHOMAGENESIS
by: Y. Lu, et al.
Published: (2025)
394 | RUXOLITINIB TARGETS STAT1‐STAT3 COOPERATIVELY IN LARGE GRANULAR LYMPHOCYTIC LEUKEMIA
by: A. Marouf, et al.
Published: (2025)
UCLI01 | ADVANCES IN DLBCL MANAGEMENT: HIGHLIGHTS FROM CHINA
by: D. Zhao
Published: (2025)
Treatment‐Free Remission in Chronic Phase Chronic Myeloid Leukemia After Nilotinib De‐Escalation: 96‐Week Update of the DANTE Study
by: Alessandra Iurlo, et al.
Published: (2025)